A product corresponding to formula (I) or its ketonic tautomer form (II) ##STR00001##
which is 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one, a process for the preparation and use of the product corresponding to formula (I) or its tautomeric form (II), a process for the preparation and use, particularly for the production of synthesis intermediates.

Patent
   RE39755
Priority
Jan 17 2000
Filed
Feb 03 2005
Issued
Jul 31 2007
Expiry
Jan 17 2021
Assg.orig
Entity
Large
0
6
all paid
1. A compound having the formula (I) or its ketonic tautomer form (II) ##STR00004##
4. A process for the preparation of the compound having the formula (I) or (II), ##STR00005##
in which 5-nitro-3H-benzofuran-2-one is reacted, at a temperature above 30° C., with pentanoic anhydride and a salt of pentanoic acid, optionally in the presence of pentanoic acid, then the resulting reaction mixture is acidified, and then the above compound is isolated.
2. A compound having the formula I according to claim 1, which is 3(1-hydroxy-pentylidene)-5nitro-3H-benzofuran-2-one.
3. A compound to formula II according to claim 2 which is 3-(1-oxopentyl)-5-nitro-3H-benzofuran-2-one.
5. A process according to claim 4, in which 1 mole of 5-nitro-3H-benzofuran-2-one is reacted with 1 to 5 moles of pentanoic anhydride, 0.1 to 2 moles of a salt of pentanoic acid and 0 to 1.5 moles of pentanoic acid, then the resulting reaction mixture is acidified and then the above compound is isolated.
6. A process according to claim 4, in which 1 mole of 5-nitro-3H-benzofuran-2-one is reacted with 2 moles of pentanoic anhydride and 1 mole of a salt of pentanoic acid, then the resulting reaction mixture is acidified, and then the above compound is isolated.
7. A process according to claim 4, in which the salt of pentanoic acid is the salt of sodium, potassium or a salt of tertiary amine.
8. A prowess process according to claim 4, in which the salt of pentanoic acid is produced extemporaneously from pentanoic acid and a base.
9. A process according to claim 4, in which the salt of pentanoic acid is produced in situ from pentanoic acid and sodium carbonate.
10. A process according to claim 4, in which the reaction mixture is acidified with sulfuric acid.
11. A process according to claim 4, in which the above formula (I) or its tautomeric form (II) is purified by recrystallisation in acetic acid.
0. 12. Synthesis intermediate produced using the compound of formula (I) or of its tautomeric form (II) as claimed in claim 1.
0. 13. 2-butyl-5-nitro-benzofuran-2-one produced using the compound of formula (I) or of its tautomeric form (II) as claimed in claim 1.

The present invention relates to 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one and to its ketonic tautomer form 3-(1-oxo-pentyl)-5-nitro-3H-benzofuran-2-one.

3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one is a new compound which may be used as a synthesis intermediate. In particular, it may be converted to 2-butyl-5-nitrobenzofuran by hydrolysis, decarboxylation and cyclisation, by simple heating in an acid medium.

2-butyl-5-nitrobenzofuran may act as an intermediate in the synthesis of an antiarrythmic, dronedarone.

The present invention provides, therefore, 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one corresponding to formula (I) ##STR00002##
and its ketonic tautomer form, 3-(1-oxo-pentyl)-5-nitro-3H-benzofuran-2-one corresponding to formula (II) ##STR00003##

The present invention also provides a process for the preparation of the compound corresponding to formula (I) and its ketonic tautomer form (II).

Finally, the present invention provides the use of the compound corresponding to formula (I) or its ketonic tautomer form (II) as a synthesis intermediate, particularly for the preparation of active pharmaceutical principles.

In particular, the present invention provides the compound corresponding to formula (I) and the preparation thereof.

This preparation is characterised in that 5-nitro-3H-benzofuran-2-one is reacted, at a temperature above 30° C., with pentanoic anhydride and a salt of pentanoic acid, optionally in the presence of pentanoic acid, then the resulting reaction mixture is acidified, and then the expected product is isolated.

This method of operating constitutes an improvement to the process described by J. N. Chatterjea, J. Indian Chem. Soc. Vol. 33 no. 3, 1956, p. 175-182 and J. Indian Chem. Soc. Vol. 34, no.4, 1957, p. 299-305.

This improvement to the process relates to the acidification of the reaction mixture at the end of the reaction which allows better isolation of the expected product. A second improvement relates to the reduction in the amount of acid anhydride required for the reaction.

Under preferential conditions for carrying out the process according to the invention, 1 mole of 5-nitro-3H-benzofuran-2-one is reacted with 1 to 5 moles of pentanoic anhydride, 0.1 to 2 moles of a salt of pentanoic acid, and 0 to 1.5 moles of pentanoic acid, then the resulting reaction mixture is acidified, and then the expected product is isolated, if desired.

Under other preferential conditions for carrying out the process according to the invention, one mole of 5-nitro-3H-benzofuran-2-one is reacted with two moles of pentanoic anhydride and one mole of a salt of pentanoic acid, then the resulting reaction mixture is acidified, then the expected product is isolated.

In the implementation of the process according to the invention, the salt of pentanoic acid may be a salt of sodium, potassium or of tertiary amine. This salt may be prepared extemporaneously, preferably in situ, from pentanoic acid and a base. The base may be sodium carbonate.

In the implementation of the process according to the invention, the resulting reaction mixture is brought into contact with an acid. This acid will be preferably dilute sulfuric acid; indeed, it permits better recovery of the expected final product.

Still under preferential conditions for carrying out the process, the crude product obtained may be recrystallised in an acid. This acid will be advantageously acetic acid.

The present invention also provides the use of the product corresponding to formula (I) or its tautomeric form (II) for the production of synthesis intermediates. In particular, it provides the production of 2-butyl-5-nitro-benzofuran-2-one 2-butyl-5-nitro-benzofuran which may act as an intermediate in the synthesis of an antiarrhythmic agent, dronedarone.

The examples below will permit a better understanding of the invention.

The following are charged to a three-necked flask:

The mixture is cooled to 20° C. and the following are added gradually within 15 minutes:

The temperature of the mixture rises to about 40° C.

The suspension is then cooled to 20° C. and the precipitate is filtered. It is washed with 250 ml of deionised water then with 250 ml of heptane.

After oven drying under reduced pressure at 60° C., a crude product with a purity of 95% is obtained.

Pure 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one is obtained by recrystallisation in acetic acid.

The analysis of the product is as follows:

Melting point: 164° C. (DSC)
Elemental analysis (theoretical): C 59.1% (59.3%), H 5.0% (4.9%), N
5.4% (5.3%)
NMR (H): 200 MHz
Solvent: DMSO
δ = 0.90 ppm Triplet J=7.1Hz 3H
δ = 1.37 ppm Multiplet 2H
δ = 1.60 ppm Multiplet 2H
δ = 2.94 ppm Triplet J=7.9Hz 2H
δ = 7.30 ppm Doublet JH7-H6=8.9Hz 1H
δ = 8.05 ppm Quadruplet JH6-H7=8.9Hz; JH6-H4=2.3Hz 1H
δ = 8.38 ppm Doublet JH4-H6=2.3Hz 1H

The following are charged to a three-necked flask:

The mixture is brought to reflux, with stirring, over a period of 8 hours, the internal temperature being in the vicinity of 116° C.

An orange-coloured solution is gradually obtained with the liberation of gas.

The solution is cooled to ambient temperature and 50 g of water are added, then the solution is extracted twice under hot conditions with 140 g of heptane.

The combined organic phases are treated with 250 g of water and the pH is adjusted to 8 by adding a 30% potash solution (about 20 ml), then the aqueous phase is drawn off.

The separated organic phase is then dried by azeotropic distillation of water then the solvent is removed by distillation and the resulting oil is heated under reduced pressure in order to remove the traces of solvent.

A slightly yellow oil which crystallises at ambient temperature is thus obtained.

The 2-butyl-5-nitrobenzofuran obtained has a purity (high pressure liquid chromatography by external standardisation with respect to a reference standard) greater than 98% and a residual amount of heptane, by vapour phase chromatography, of less than 1.5%.

The NMR (H) spectrum 200 MHz (solvent: DMSO) is as follows:

δ = 0.90 ppm Triplet J=7.2Hz 3H
δ = 1.35 ppm Multiplet 2H
δ = 1.66 ppm Multiplet 2H
δ = 2.80 ppm Triplet J=7.4Hz 2H
δ = 6.80 ppm Singlet 1H
δ = 7.70 ppm Doublet JH7H6=9Hz 1H
δ = 8.11 ppm Doublet of JH6H7=9Hz; JH6H42.3Hz 1H
doublet
δ = 8.47 ppm Doublet JH4H62.3Hz 1H

Schouteeten, Alan, Mordacq, Francoise

Patent Priority Assignee Title
Patent Priority Assignee Title
3248401,
4252817, Mar 05 1976 Sandoz Ltd. Substituted-2,3-dihydrobenzofuran-2-ones
5223510, Aug 06 1990 Sanofi Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
5444056, Feb 07 1989 Elf Sanofi Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them
5854282, Aug 11 1994 Karo Bio AB 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
WO9605190,
////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 15 2000SCHOUTEETEN, ALAINClariant FranceASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0182930602 pdf
Dec 15 2000MORDACQ, FRANCOISEClariant FranceASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0182930602 pdf
Feb 03 2005Clariant France(assignment on the face of the patent)
Sep 14 2006SCHOUTEETEN, ALAINClariant FranceASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0183940837 pdf
Sep 14 2006MORDACQ, FRANCOISEClariant FranceASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0183940837 pdf
Sep 11 2007CLARIANT FRANCE CLARIANT SPECIALTY FINE CHEMICALS FRANCE ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0250000952 pdf
Aug 25 2008CLARIANT SPECIALTY FINE CHEMICALS FRANCE WEYLCHEM LAMOTTE S A S CHANGE OF NAME SEE DOCUMENT FOR DETAILS 0342150470 pdf
Jul 01 2011CLARIANT SPECIALTY FINE CHEMICALS FRANCE CLARIANT SPECIALTY FINE CHEMICALS FRANCE RECEIVING ADDRESS0311420412 pdf
Date Maintenance Fee Events
Jul 02 2010M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Feb 06 2014ASPN: Payor Number Assigned.
Jul 31 2014M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jul 31 20104 years fee payment window open
Jan 31 20116 months grace period start (w surcharge)
Jul 31 2011patent expiry (for year 4)
Jul 31 20132 years to revive unintentionally abandoned end. (for year 4)
Jul 31 20148 years fee payment window open
Jan 31 20156 months grace period start (w surcharge)
Jul 31 2015patent expiry (for year 8)
Jul 31 20172 years to revive unintentionally abandoned end. (for year 8)
Jul 31 201812 years fee payment window open
Jan 31 20196 months grace period start (w surcharge)
Jul 31 2019patent expiry (for year 12)
Jul 31 20212 years to revive unintentionally abandoned end. (for year 12)